Linked Life Data

16838659

Source:http://linkedlifedata.com/resource/pubmed/id/16838659

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2006-7-14
pubmed:abstractText
Recently, new types of interferon (IFN) agents, such as pegylated IFN (PEG-IFN) and consensus IFN, have been developed for strong therapeutic effect and used in clinical stage. PEG-IFN, which is the conjugation of IFN and polyethylene glycol, was designed to long circulate in blood and decrease antibody production. Consensus IFN was designed to combine amino acid frequently appeared in IFN-alpha subtypes. Although they improved IFN therapy, it is also important to pay attention to side effect. Characteristics of new type IFN agents were summarized focused on their pharmaceutical designs.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0047-1852
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1374-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
[Pharmaceutical device of IFN].
pubmed:affiliation
Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University.
pubmed:publicationType
Journal Article, English Abstract, Review